Chemed Co. (NYSE:CHE) Stake Decreased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. trimmed its holdings in Chemed Co. (NYSE:CHEFree Report) by 5.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 996 shares of the company’s stock after selling 60 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Chemed were worth $599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. Kayne Anderson Rudnick Investment Management LLC boosted its position in Chemed by 2.6% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 580,316 shares of the company’s stock worth $314,868,000 after acquiring an additional 14,651 shares during the period. William Blair Investment Management LLC lifted its holdings in Chemed by 2.7% in the second quarter. William Blair Investment Management LLC now owns 475,372 shares of the company’s stock worth $257,927,000 after purchasing an additional 12,705 shares during the period. Impax Asset Management Group plc grew its position in Chemed by 4.7% in the 3rd quarter. Impax Asset Management Group plc now owns 332,757 shares of the company’s stock valued at $199,977,000 after buying an additional 14,814 shares in the last quarter. TD Asset Management Inc grew its position in Chemed by 10.9% in the 2nd quarter. TD Asset Management Inc now owns 282,753 shares of the company’s stock valued at $153,416,000 after buying an additional 27,800 shares in the last quarter. Finally, Epoch Investment Partners Inc. increased its stake in Chemed by 22.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 223,134 shares of the company’s stock valued at $121,068,000 after buying an additional 40,358 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Chemed Stock Performance

CHE opened at $558.64 on Friday. The stock’s fifty day moving average is $580.37 and its 200-day moving average is $565.40. Chemed Co. has a one year low of $523.33 and a one year high of $654.62. The company has a market capitalization of $8.41 billion, a PE ratio of 28.23, a P/E/G ratio of 2.40 and a beta of 0.46.

Chemed (NYSE:CHEGet Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing analysts’ consensus estimates of $5.76 by ($0.12). Chemed had a net margin of 12.69% and a return on equity of 27.86%. The business had revenue of $606.18 million during the quarter, compared to analyst estimates of $612.22 million. During the same period in the previous year, the company posted $5.32 earnings per share. Chemed’s revenue was up 7.4% compared to the same quarter last year. On average, equities research analysts forecast that Chemed Co. will post 21.43 EPS for the current fiscal year.

Chemed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Monday, November 18th will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $2.00 annualized dividend and a yield of 0.36%. Chemed’s dividend payout ratio (DPR) is 10.11%.

Analysts Set New Price Targets

Separately, Royal Bank of Canada decreased their price objective on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th.

Read Our Latest Research Report on CHE

Insiders Place Their Bets

In related news, Director George J. Walsh III sold 200 shares of Chemed stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $577.95, for a total value of $115,590.00. Following the transaction, the director now owns 3,446 shares of the company’s stock, valued at approximately $1,991,615.70. This trade represents a 5.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $598.81, for a total transaction of $1,197,620.00. Following the sale, the chief executive officer now directly owns 103,735 shares of the company’s stock, valued at $62,117,555.35. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,313 shares of company stock worth $2,527,495. 3.32% of the stock is owned by insiders.

About Chemed

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Stories

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.